Dramatic Decline of PSA and Symptom Improvement after Estramustine Withdrawal in a Hormone-refractory Prostate Cancer Patient.
10.4111/kju.2007.48.7.751
- Author:
Kyo Ik MO
1
;
Ki Ho KIM
;
Young Jin SEO
;
Kyung Seop LEE
Author Information
1. Department of Urology, College of Medicine, Dongguk University, Gyeongju, Korea. ksleemd@dongguk.ac.kr
- Publication Type:Case Report
- Keywords:
Prostate cancer;
Estramustine;
Chemotherapy
- MeSH:
Disease Progression;
Drug Therapy;
Estramustine*;
Humans;
Prostate*;
Prostatic Neoplasms*
- From:Korean Journal of Urology
2007;48(7):751-753
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
In some patients with prostate cancer and who manifest disease progression during maximal androgen blockade(MAB) therapy, discontinuation of antiandrogen treatment might result in a significant fall in the level of serum prostate-specific antigen(PSA), and this is often correlated with clinical improvement(antiandrogen withdrawal syndrome). However, a decline in the PSA level after the withdrawal of estramustine phosphate is extremely rare. We report here on a case of dramatic decline in the PSA level after withdrawal of estramustine phosphate in a patient with hormone refractory prostate cancer.
